Systemic amyloidoses are potentially lethal ... amyloidosis and intensive chemotherapy in immunoglobulin light chain (AL) amyloidosis. These therapies often elicit substantial morbidity and ...

The investigational treatment is currently being evaluated in a 3-part phase 1 trial (ClinicalTrials.gov Identifier: NCT05521022) in adult patients with systemic amyloidosis, as well as a phase 2 open ...

This important study identifies the "H-state" as a potential conformational marker distinguishing amyloidogenic from non-amyloidogenic light chains, addressing a critical problem in protein misfolding ...

As a result, the company expects AT-02 to bind specifically to amyloid in systemic amyloidosis patients ... Phase 1 trial and a Phase 2 open label extension trial in ATTR and AL amyloidosis patients.

Stand Up To Cancer (SU2C) today announced a collaboration with Johnson & Johnson aimed at supporting research testing a combination of two types of targeted therapies, teclistamab and daratumumab, to ...

Different types of systemic amyloidosis are recognized depending ... amyloid A amyloidosis (AA), immunoglobulin light chain amyloidosis (AL) and transthyretin-related amyloidosis (ATTR).

Almost four years after it was approved in Europe to treat the incurable rare disease systemic amyloid light-chain (AL) amyloidosis, Johnson & Johnson’s Darzalex has been given the go-ahead for ...

In a review article of AL amyloidosis "Systemic Light Chain Amyloidosis," Vaishali Sanchorawala, MD, director of the ...

The investigational treatment is currently being evaluated in a 3-part phase 1 trial (ClinicalTrials.gov Identifier: NCT05521022) in adult patients with systemic amyloidosis, as well as a phase 2 ...